TransMedics Group Raises FY2026 Sales Guidance from $727.000M-$757.000M to $737.000M-$757.000M vs $732.700M Est

Benzinga Newsdesk www.benzinga.com Positive 94.2%

Neg 0% Neu 0% Pos 94.2%

TransMedics Group (NASDAQ:TMDX) raises FY2026 sales outlook from $727.000 million-$757.000 million to $737.000 million-$757.000 million vs $732.700 million estimate.